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SPECIAL REVIEW: PLATELET RECEPTOR SHEDDING
Regulation of A disintegrin and metalloproteinase (ADAM) family
sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and
rhomboids
Alexandra L. Matthews, Peter J. Noy, Jasmeet S. Reyat, & Michael G. Tomlinson
School of Biosciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham, UK
Abstract
A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are ubiquitous transmembrane
“molecular scissors” which proteolytically cleave, or shed, the extracellular regions of other
transmembrane proteins. ADAM10 is essential for development because it cleaves Notch
proteins to induce Notch signaling and regulate cell fate decisions. ADAM17 is regarded as a
first line of defense against injury and infection, by releasing tumor necrosis factor α (TNFα) to
promote inflammation and epidermal growth factor (EGF) receptor ligands to maintain epi-
dermal barrier function. However, the regulation of ADAM10 and ADAM17 trafficking and
activation are not fully understood. This review will describe how the TspanC8 subgroup of
tetraspanins (Tspan5, 10, 14, 15, 17, and 33) and the iRhom subgroup of protease-inactive
rhomboids (iRhom1 and 2) have emerged as important regulators of ADAM10 and ADAM17,
respectively. In particular, they are required for the enzymatic maturation and trafficking to the
cell surface of the ADAMs, and there is evidence that different TspanC8s and iRhoms target the
ADAMs to distinct substrates. The TspanC8s and iRhoms have not been studied functionally on
platelets. On these cells, ADAM10 is the principal sheddase for the platelet collagen receptor
GPVI, and the regulatory TspanC8s are Tspan14, 15, and 33, as determined from proteomic
data. Platelet ADAM17 is the sheddase for the von Willebrand factor (vWF) receptor GPIb, and
iRhom2 is the only iRhom that is expressed. Induced shedding of either GPVI or GPIb has
therapeutic potential, since inhibition of either receptor is regarded as a promising anti-
thrombotic therapy. Targeting of Tspan14, 15, or 33 to activate platelet ADAM10, or iRhom2
to activate ADAM17, may enable such an approach to be realized, without the toxic side effects
of activating the ADAMs on every cell in the body.
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Introduction
Protein cleavage, or “shedding,” of the extracellular regions (ecto-
domains) of transmembrane proteins has emerged as a key regula-
tory process in cell biology. “Sheddases” can modulate signaling
on host or neighboring cells either directly through the regulation
of cell surface receptors or indirectly through the release of soluble
mediators from their membrane-bound precursors [1]. The
ADAMs (A disintegrin and metalloproteinases) are one of the
major proteinase families that function as sheddases. They are
characterized by a modular domain structure, which is comprised
of an N-terminal signal sequence followed by a prodomain, metal-
loprotease domain, disintegrin domain, cysteine-rich region, EGF-
like domain (not in ADAM10 and 17), transmembrane domain, and
a cytoplasmic tail (Figure 1). The ADAM family consists of 22
members, as identified in the human genome, of which only 12
(ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, and 33) encode
active enzymes [2].
ADAM10 and ADAM17: ubiquitous and essential
“molecular scissors”
ADAM10 (also known as Kuzbanian from its orthologous gene,
kuz, in Drosophila) and its close relative ADAM17 (also recog-
nized as tumor necrosis factor α (TNFα) converting enzyme or
TACE) are ubiquitously expressed in mammalian cells. ADAM10
and ADAM17 share 30% amino acid identity in human and are
the principal ADAM sheddases; they are capable of cleaving
numerous substrates with diverse functions, whereas other
ADAMs appear to have a more restricted substrate range [3,4].
ADAM10 has at least 40 substrates, many of which have
important roles in health and disease. These include the Notch
cell fate regulators [5–8], amyloid precursor protein (APP) [9],
cellular prion protein [10], epidermal growth factor receptor
(EGFR) ligands betacellulin and EGF [11], adhesion molecules
E-cadherin [12], N-cadherin [13], VE-cadherin [14] and CD44
[15], transmembrane chemokines CX3CL1 and CXCL16 [16], the
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low-affinity immunoglobulin E receptor CD23 [17], and vascular
endothelial growth factor receptor 2 [18]. ADAM10-deficient
mice phenocopy Notch-deficient mice; they die at embryonic
day 9.5 with multiple defects of the somites, cardiovascular, and
neuronal systems [19]. This demonstrates the key role of
ADAM10 in the activation of Notch proteins. ADAM10 appears
to have constitutive activity toward some substrates, but its activ-
ity can be upregulated by certain stimuli that induce intracellular
signaling. The activation mechanism is not clear, but the
ADAM10 transmembrane region, and not the cytoplasmic tail,
is important in this process [20]. There is also evidence that
intracellular signaling renders substrates more susceptible to clea-
vage, for example following phosphorylation of the CD44 cyto-
plasmic tail. This may then induce conformational changes and/or
dimerization in the CD44 extracellular region, to promote clea-
vage by ADAM10 [21,22].
ADAM17 appears to have at least as many substrates as
ADAM10. It is rapidly activated by a great variety of stimuli to
induce the shedding and release of soluble TNFα and the EGFR
ligands amphiregulin, epiregulin, heparin-binding EGF-like
growth factor, and transforming growth factor α (TGFα) [23].
Therefore, ADAM17 has been proposed to function as a first
line of defense against injury, by promoting inflammation and
repair of skin and intestine barrier function. Consistent with such
a function, ADAM17-deficient mice phenocopy EGFR-deficient
mice; they die shortly after birth and have skin barrier defects,
open eyes at birth, enlarged heart valves, abnormal mammary
ductal morphogenesis, and lung defects [24–28]. Other
ADAM17 substrates include the adhesion molecules ICAM-1
[29] and L-selectin [28], and TNF receptor family members
TNFRI [30] and TNFRII [28]. Several studies have investigated
the mechanism by which ADAM17 activity is regulated. Similar
to ADAM10, there is evidence that activation of ADAM17 is
dependent on its transmembrane domain but not the cytoplasmic
tail [23]. However, a second study provides evidence that the
cytoplasmic tail is important in negatively regulating ADAM17
[31]. The cytoplasmic tail promotes dimerization, which also
appears to be a feature of the ADAM10 tail [31,32].
Phosphorylation of the ADAM17 tail, by the mitogen-activated
protein kinases (MAPKs) extracellular signal-regulated kinase
(Erk) and p38, reduces dimerization, which decreases tissue
inhibitor of metalloproteinase-3 (TIMP3) interaction with the
extracellular region of ADAM17 and promotes activation [31].
Another reported regulatory mechanism involves direct inhibition
of the ADAM17 extracellular region by protein disulfide isomer-
ize [33–35]. The latter can interact with ADAM17 and alter the
disulfide bonding within the membrane-proximal cysteine-rich
region. This appears to convert the ADAM17 extracellular region
from an extended “open” active conformation into a “closed”
inactive conformation [33]. Finally, the lipid second messenger
ceramide 1-phosphate, a product of ceramide kinase, can interact
with ADAM17 and inhibit its activity by an as yet undefined
mechanism [36].
On platelets, ADAM10 is the major sheddase for GPVI
[37,38], the main collagen-activated receptor which has recently
been shown to also bind fibrin [39,40]. ADAM17 is a sheddase
for GPIbα [41] and GPV [42] of the GPIb–IX–V complex, which
has a variety of ligands including von Willebrand factor (vWF),
thrombin, coagulation factors XI and XII, P-selectin, and the
leukocyte integrin αMβ2 [43]. GPIb-IX-V is essential for hemos-
tasis and GPVI has a minor role, but both are potential anti-
platelet drug targets because they promote thrombosis [44]. The
physiological role of their shedding is not clear, since mice with
platelets deficient in ADAM10, ADAM17, or both have normal
platelet size and count [37]. However, ADAM17 appears to con-
stitutively shed GPIbα, since mice with ADAM17-knockout pla-
telets have reduced plasma levels of glycocalicin, a soluble
fragment of GPIbα [37]. Shedding may be important in disease
processes. For example, Staphylococcus aureus α-toxin binds to
and activates ADAM10 [45], one consequence of which is shed-
ding of GPVI which contributes to lethal sepsis in mice [46].
Furthermore, soluble GPVI is elevated in human patients in
several diseases, including coronary artery disease and ischemic
stroke [47]. ADAM10 and ADAM17 have some substrates in
common, and there is evidence that ADAM10 can shed GPV
and that ADAM17 sheds GPVI [37,38]. Indeed, expression levels
of GPVI and GPIb are mildly elevated on ADAM10/17 double-
deficient platelets, but not on single-knockout platelets [37]. The
importance of ADAM10/17 shedding of other substrates in the
platelet/megakaryocyte lineage is not known. The additional
ADAM10 substrates include Notch proteins, APP, CD44, EGF,
and CD84, although only the latter has been confirmed as an
Figure 1. A diagrammatic representation of
ADAM10 interacting with each of six
TspanC8s (A) and ADAM17 interacting with
each of iRhom1 and 2 (B). Note that the
TspanC8s differ in the number of N-linked gly-
cosylation sites (dark gray ovals) and in the
lengths of their cytoplasmic tails (the Tspan5
C-terminus is shortest at 15 amino acids and the
Tspan10 N-terminus is longest at 77 amino
acids). The iRhoms are relatively similar but
differ in N-glycosylation.
2 A. L. Matthews et al. Platelets, Early Online: 1–9
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 B
irm
ing
ha
m]
 at
 04
:57
 23
 Ju
ne
 20
16
 
ADAM10 substrate on platelets and its function is not clear [48].
An additional ADAM17 substrate on platelets is the semaphorin
Sema4D, which binds to plexin family receptors and amplifies
GPVI-induced platelet activation [49,50].
The ubiquitous expression of ADAM10 and ADAM17 and full
repertoire of their substrates is reflected in the pleiotropic func-
tion of these enzymes, with roles in cell adhesion, proliferation,
differentiation, migration, immunity, and receptor-ligand signal-
ing [3,4]. However, the mechanisms by which ADAM10 and
ADAM17 activity are regulated are not fully understood. This
review will cover the emerging role of two families of multi-
transmembrane proteins in the regulation of ADAM10 and
ADAM17, namely the tetraspanins and rhomboids, respectively.
Regulation of ADAM10 by tetraspanins
Tetraspanins regulate the trafficking and membrane
dynamics of other transmembrane proteins
The tetraspanins are an evolutionarily conserved superfamily of
33 transmembrane proteins in mammals, which extends to flies,
worms, multicellular fungi, and plants [51,52]. Tetraspanins con-
tain four transmembrane domains that delineate two extracellular
loops of unequal size (the larger of which has four to eight
conserved cysteine residues that form structurally important dis-
ulfide bonds), one intracellular loop, and intracellular N- and
C-termini (Figure 1). Structural studies have revealed that tetra-
spanins fold to form compact, rod-shaped structures that protrude
3–5 nm from the plasma membrane [53]. Tetraspanins are not
generally believed to have ligands or to function as cell surface
receptors, but instead they are thought to self-associate with one
another and with their so-called “partner” proteins into nanoclus-
ters. Tetraspanin partner proteins include ADAM10, integrins,
and members of the immunoglobulin superfamily [51,52].
A recent super-resolution microscopy study revealed that most
tetraspanin nanoclusters appear to contain only one type of tetra-
spanin [54]. This helps to explain the specific functions that have
been assigned to distinct tetraspanins through gene-knockout stu-
dies. These include the role of tetraspanin CD151 in regulating its
laminin-binding integrin partner proteins α3β1, α6β1, and α6β4
[52]. Indeed, CD151 promotes adhesion strengthening of cells to
laminin [55], integrin recycling from the plasma membrane
[56,57], and glycosylation of α3 during biosynthesis [58] and
restricts the lateral mobility of α6 in the plasma membrane [59].
Tetraspanin CD81 regulates glycosylation of the B cell signaling
protein CD19 and is essential for its trafficking to the plasma
membrane [60]. On endothelial cells, tetraspanin Tspan12 pro-
motes Frizzled 4 clustering and signaling in response to its ligand
norrin [61], while tetraspanins CD9, CD151, and CD63 promote
inflammatory leukocyte capture by clustering adhesion molecules
ICAM-1, VCAM-1 [62], and P-selectin [63], respectively.
Importantly, these findings are all supported by tetraspanin-
knockout or -knockdown studies, in which the tetraspanin knock-
out phenocopies that of the partner protein. Moreover, human
mutations in CD151, CD81, and Tspan12 cause diseases that
are consistent with functional impairment of the respective part-
ners [64–67].
In platelets, tetraspanin-deficient mice have revealed a positive
role for CD151 and Tspan32 in hemostasis, which is proposed to
be mediated by their regulation of outside-in signaling by the
major platelet integrin αIIbβ3 [68,69]. However, this is likely to
be a fine-tuning role, or an indirect effect, because the CD151 and
Tspan32-knockout phenotypes are less severe than the αIIbβ3
knockout, and their copy numbers on platelets are several-fold
lower than the integrin [70–72]. CD82 plays an opposing role to
CD151 and Tspan32, since CD82-deficient mice have reduced
bleeding times and enhanced clot retraction [73]. Surface expres-
sion levels of αIIbβ3 are approximately 30% elevated in the
absence of CD82 [73], but again regulation of the integrin is
unlikely to be direct, because of the relatively low CD82 copy
number [72]. Platelets deficient in CD9 or CD63 have subtle
defects, suggesting relatively minor roles for these tetraspanins
in hemostasis [74,75].
The TspanC8 subgroup of tetraspanins interact with
ADAM10 and promote its exit from the endoplasmic
reticulum and enzymatic maturation
The first clues to ADAM10 regulation by tetraspanins were the
findings that it co-immunoprecipitates with tetraspanins in human
leukocyte cell lines and that tetraspanin antibodies promote
ADAM10 activity, as measured by the shedding of ADAM10
substrates such as EGF [76]. Subsequently, we and others showed
that six largely unstudied tetraspanins (Tspan5, 10, 14, 15, 17, and
33) co-immunoprecipitate with ADAM10 in stringent lysis buf-
fers, whereas other tetraspanins do not [77,78]. The ADAM10-
interacting tetraspanins are related by amino acid sequence, with
the human homologs ranging from 78% amino acid identity
between Tspan5 and 17 to 26% identity between the most dis-
tantly related Tspan10 and 15. These tetraspanins were termed the
TspanC8 subgroup due to the eight cysteine residues that they
possess within their large extracellular loop [77,78]; other tetra-
spanins have four, six, or seven. An unrelated tetraspanin,
Tspan12, was also reported to regulate ADAM10 [79], but this
is now thought to be an indirect effect [77,78], potentially
mediated via Tspan12 interaction with, and/or regulation of,
TspanC8 tetraspanins. Overexpression of any of the six
TspanC8s in cell lines promotes ADAM10 exit from the endo-
plasmic reticulum (ER) and its enzymatic maturation [77, 78, 80]
(Figure 2). This is the process by which the prodomain is
removed by proprotein convertases, such as Furin, in the Golgi
to unmask the catalytic site [81]. Different cell types have their
own TspanC8 repertoires [78]. Knockdown or knockout of the
most highly expressed TspanC8, in several primary cells and cell
lines that have been studied, prevents ADAM10 ER exit and
trafficking to the plasma membrane [77, 78, 80]. Importantly,
TspanC8-knockout mice and flies yield phenotypes that are con-
sistent with these data. In mice, Tspan33 is the predominant
Figure 2. Regulation of ADAM10 and ADAM17 exit from the endoplas-
mic reticulum (ER), enzymatic maturation, and trafficking to the plasma
membrane by TspanC8s and iRhoms, respectively. Only Tspan14, 15, 33,
and iRhom2 are depicted because of their expression in human platelets.
Enzymatic maturation involves cleavage of the ADAM prodomain in the
Golgi by proprotein convertases.
DOI: 10.1080/09537104.2016.1184751 TspanC8 and iRhom regulation of ADAM10 and ADAM17 3
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TspanC8 in the red blood cell lineage; Tspan33 deficiency in
mice results in impaired red blood cell production and substan-
tially reduced ADAM10 expression on red cells [78]. In
Drosophila, there are three TspanC8s, and these are required for
Notch activity and normal fly development [77], consistent with
the key role for ADAM10 in Notch activation. Taken together,
these studies demonstrate an essential role for the TspanC8s in
promoting ADAM10 intracellular trafficking (Figure 2).
ADAM10 “six appeal”: evidence that ADAM10 can be
regarded as six different molecular scissors, depending upon
which TspanC8 it is partnered with
An important question arising from the aforementioned studies is
why six TspanC8 tetraspanins have evolved to regulate ADAM10
trafficking. One theory is that each of the six TspanC8 tetraspa-
nins may target ADAM10 to distinct subcellular localizations
and/or substrates. Different TspanC8s certainly appear to have
different subcellular localizations when transfected into cell
lines, with some promoting ADAM10 trafficking to intracellular
compartments and others to the plasma membrane [77].
Moreover, there is growing evidence to suggest that the different
TspanC8s can promote or suppress the ADAM10-mediated shed-
ding of specific substrates. For example, Tspan5, Tspan10, and
Tspan14 appear to be positive regulators of Notch signaling,
whereas Tspan15 and Tspan33 are negative regulators [77, 82,
83]. Similarly interesting data have been reported for other
ADAM10 substrates: N-cadherin cleavage is specifically pro-
moted by Tspan15 [80, 82, 84], APP cleavage is inhibited by
Tspan15 in U2OS and PC3 cells [82], but promoted by this
tetraspanin in HEK and N2A cells [80], and CD44 cleavage is
promoted by Tspan5 but not Tspan15 [82]. These studies each
used TspanC8 overexpression or knockdown in cell lines, and
some differences were observed between different cells, thus
complicating the interpretations. This likely reflects the different
endogenous TspanC8 repertoires, and potentially associated traf-
ficking proteins, of each cell type. There is scope for the cyto-
plasmic tails of TspanC8s to interact with specific trafficking
proteins, since these tails show no substantial sequence similarity
between different TspanC8s. They are also relatively long for
tetraspanins, with N- and C-termini having average lengths of
29 and 36 amino acids, respectively, which are two to three
times longer than is typical for most other tetraspanins.
However, TspanC8 interactions with trafficking proteins have
yet to be identified.
To begin to determine the mechanisms responsible for differ-
ent subcellular localization and shedding by distinct TspanC8–
ADAM10 complexes, their lateral mobility and associated pro-
teins have been investigated [82]. ADAM10 single-particle track-
ing studies using total internal reflectance fluorescence
microscopy suggest that Tspan15 promotes ADAM10 lateral
mobility at the plasma membrane, but Tspan5 does not. In addi-
tion, proteomic studies identified a number of proteins that pre-
ferentially co-immunoprecipitate with Tspan5 versus Tspan15
[82]. Furthermore, we have used mutant forms of TspanC8s and
ADAM10 to show that the TspanC8–ADAM10 interaction is
largely mediated by the main extracellular region of the
TspanC8. This binds to the membrane-proximal stalk, disintegrin,
and cysteine-rich domain regions of ADAM10 [84]. However,
there are some differences between TspanC8s in the precise
binding regions that they require on ADAM10. This suggests
that ADAM10 may adopt a different conformation, depending
on which TspanC8 it is associated with [84]. This may in part
dictate substrate specificity. An additional possibility is that
TspanC8s target ADAM10 to a substrate by directly binding to
the substrate. There is no evidence for this at present, but it is
interesting that some ADAM10 substrates, including GPVI and
CD44, have been reported to interact with an as yet unidentified
tetraspanin [71, 85].
ADAM10 substrates on platelets include GPVI, GPV, APP,
CD44, CD84, and EGF. It has yet to be investigated whether
specific TspanC8s promote or suppress shedding of any of these
substrates on platelets, although speculations can be made based
on studies in other cell types (Figure 3). However, investigating
such speculations will be difficult because it is not possible to
genetically modify the anucleate platelet directly, and knockout
mice are only available for Tspan33, which does not appear to be
expressed in mouse platelets [78, 86]. Furthermore, monoclonal
antibodies have yet to be generated for any TspanC8. Quantitative
proteomics of human and mouse platelets [86, 87] nevertheless
allow TspanC8 copy numbers to be estimated (Table I). Human
platelets express similar levels of Tspan14, 15, and 33 [87],
whereas mouse platelets only express Tspan14 [86]. The latter is
consistent with our quantitative PCR analyses of mouse megakar-
yocytes, which show Tspan14 to be the most highly expressed
TspanC8 in these cells [78]. This suggests a more limited scope
for ADAM10 regulation by TspanC8s in mouse platelets.
Nevertheless, we have detected Tspan5, 17, and 33 mRNA in
mouse megakaryocytes, albeit at relatively low levels [71, 78],
indicating that these additional TspanC8s might regulate
ADAM10 during megakaryocyte development. In keeping with
their intimate relationship, the total TspanC8 protein copy number
is comparable to the ADAM10 copy number in both human and
mouse platelets (Table I).
We have confirmed Tspan14 expression in human and mouse
platelets by the generation of a polyclonal western blotting anti-
body, and we have further confirmed its interaction with
ADAM10 on these cells [84]. To investigate whether TspanC8s
might affect GPVI shedding, we have adopted a cell line transfec-
tion model. Strikingly, Tspan14 overexpression suppresses
ADAM10 cleavage, but the other TspanC8s have no effect [84].
We speculate that Tspan14 functions to protect GPVI from
ADAM10 shedding on resting platelets, but may be induced to
promote shedding, or release its inhibitory effect on ADAM10,
upon platelet activation. This would help to explain why GPVI is
not cleaved in resting platelets, but is rapidly cleaved in response
to various stimuli including its physiological ligand collagen,
shear stress, activated coagulation factor Xa, GPVI antibodies,
and other platelet-activating agonists [47]. Since GPVI is
regarded as a promising anti-platelet drug target to treat throm-
bosis [44], the induction of GPVI shedding by targeting the
Tspan14–ADAM10 complex has some potential.
Taken together, emerging evidence indicates that different
TspanC8s regulate shedding of distinct ADAM10 substrates.
This may be due to effects on ADAM10 subcellular localization,
conformation, and/or direct TspanC8–substrate interactions. This
leads us to suggest that ADAM10 should not be regarded as a
single molecular scissor, but instead can exist as one of six
different scissors, depending on which TspanC8 it is partnered
with.
Regulation of ADAM17 by rhomboids
The rhomboid superfamily of intramembrane proteases
The rhomboids, like the tetraspanins, are an evolutionarily conserved
superfamily of multi-transmembrane proteins [88, 89]. However,
rhomboids have six or seven transmembrane domains and are even
more widespread than tetraspanins, being present in bacteria as well
as animals, plants, and fungi. Rhomboids are serine proteases (or
catalytically inactive non-proteases), which are characterized by the
presence of the active protease site within the membrane, where
4 A. L. Matthews et al. Platelets, Early Online: 1–9
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transmembrane substrates are cut [90]. The founding member of the
rhomboid superfamily is Drosophila rhomboid-1, which releases
ligands for the EGF receptor. The five mammalian active rhomboids
are RHBDL1-4 and PARL. RHBDL1-4 are expressed on the
secretory pathway and are not well understood, with definitive
substrates yet to be identified. RHBDL1-3 may promote the release
of secreted proteins, while RHBDL4 is ER localized and may
regulate ER-associated degradation, which is a quality-control pro-
cess to remove incorrectly folded proteins. In contrast, PARL is
relatively well studied and important for mitochondrial structure
and function, with potential roles in type 2 diabetes and
Parkinson’s disease [88, 89]. The non-protease rhomboids lack
essential residues within the catalytic site that are required for
protease activity. There are nine non-protease rhomboids in mam-
mals. Of these, derlins 1–3 appear to regulate ER-associated degra-
dation, while RHBDD2, RHBDD3, TMEM115, and UBAC2 are
relatively poorly understood [88, 89]. The other two non-protease
rhomboids are iRhom1 and iRhom2, which have recently emerged as
regulators of ADAM17 [91–93] and will be the focus of the remain-
der of the review.
iRhom1 and 2 interact with ADAM17 and promote its exit
from the ER and enzymatic maturation
Amongst the non-protease rhomboids, the iRhoms are the most
closely related by amino acid sequence to the active rhomboids,
Figure 3. ADAM10 and ADAM17 substrate
cleavage on the megakaryocyte/platelet surface.
(A) GPVI is not constitutively cleaved on pla-
telets but is cleaved upon platelet activation.
Some other ADAM10 substrates, GPV, Notch,
CD44, and amyloid precursor protein (APP) are
depicted, but their cleavage on platelets is not
well characterized. Nevertheless, studies on
other cell types, and in cell line models, suggest
that different TspanC8s promote cleavage of
distinct substrates. For example, Tspan14
appears to protect GPVI from cleavage, Tspan14
promotes Notch cleavage but Tspan15 inhibits,
Tspan15 cannot promote CD44 cleavage, and
Tspan15 effects on APP are cell type dependent.
(B) GPIbα is constitutively cleaved by
ADAM17. GPV and GPVI also appear to be
shed by ADAM17 following platelet activation.
Studies in other cell types suggest that
ADAM17 trafficking and activation may be
regulated by iRhom2, but this has yet to be
tested in megakaryocytes or platelets.
Table I. ADAM10 and ADAM17 are expressed at a similar copy number
to their regulatory TspanC8s and iRhoms, in human and mouse platelets.
Protein
Human platelet copy number
(Burkhart et al. 2012)
Mouse platelet copy number
(Zeiler et al. 2014)
ADAM10 4400 9889
ADAM17 670 151
iRhom1 0 0
iRhom2 1000 293
Tspan5 0 0
Tspan10 0 0
Tspan14 2000 8664
Tspan15 2500 0
Tspan17 0 0
Tspan33 2100 0
Data were obtained from quantitative proteomic studies [86,87].
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and they are the most studied [88, 89]. The two human iRhoms
share 61% amino acid identity and are characterized by seven
transmembrane domains and a relatively large cytoplasmic
N-terminus of approximately 410 amino acids (Figure 1). A
function for iRhoms was first identified in Drosophila, where it
was shown that the single iRhom in this organism counteracts the
function of active rhomboid-1 [94]. Drosophila iRhom achieves
this by interacting with transmembrane EGFR ligands and target-
ing them to the ER-associated degradation pathway, before they
can be released as active ligands by rhomboid-1 [94].
In mammals, however, this is not the role for iRhom1 and 2,
since the generation of iRhom2-deficient or mutant mice
demonstrated that this iRhom is essential for release of the
inflammatory cytokine TNFα from macrophages [91–93]. As
a result, iRhom2-deficient mice have substantially reduced
serum levels of TNFα upon inflammatory challenge with bac-
terial lipopolysaccharide and consequently reduced survival
upon infection with the intracellular bacterium Listeria mono-
cytogenes [92]. As described earlier, ADAM17 is the sheddase
for TNFα, and iRhom2 was shown to interact with ADAM17 in
the ER and to promote its enzymatic maturation and trafficking
to the cell surface [91, 92] (Figure 2). Consistent with such a
regulatory role, the iRhom2-deficient mice phenocopy myeloid-
specific ADAM17-deficient mice in an inflammatory arthritis
model, in which both strains are protected [95]. The macro-
phage phenotype observed in iRhom2-deficient mice is consis-
tent with the fact that iRhom2 expression is restricted to certain
hematopoietic cells such as macrophages, whereas iRhom1 is
more widely expressed but is not expressed in macrophages [95,
96]. This is particularly exciting from an anti-inflammatory
therapeutic angle. Targeting iRhom2 may reduce inflammation
by specifically preventing TNFα release from macrophages,
without the side effects of the widely used global TNFα-target-
ing drugs.
A recent characterization of iRhom1/2 double-deficient mice
suggests that the primary role of iRhoms is to regulate ADAM17,
since the phenotype is a remarkable phenocopy of ADAM17-defi-
cient mice [97]. In particular, the mice are born with open eyes and
die shortly after birth. Furthermore, ADAM17 maturation and
EGFR phosphorylation are almost completely absent in a panel of
iRhom1/2 double-deficient tissues, suggesting an absence of
ADAM17 activity [97]. However, an earlier study suggested that
iRhoms have functions in addition to their regulation of ADAM17,
since a different iRhom1/2-deficient mouse model has a more
severe phenotype, which results in embryonic lethality between
days 9.5 and 10.5 [96]. This discrepancy appears to be due to
differences in iRhom1 single-knockout phenotypes between the
two models. Indeed, in the more recent study, iRhom1-deficient
mice are found to be viable, albeit with impaired ADAM17 matura-
tion in brain tissue [97]. In the earlier study, however, iRhom1-
deficient mice died between 9 days and 6 weeks after birth with
defects in multiple tissues [96]. It therefore remains unclear whether
iRhoms have roles in addition to their regulation of ADAM17.
The promotion of ADAM17 maturation and trafficking to the cell
surface by iRhoms appears to extend to humans. Dominant active
iRhom2 mutations, within the N-terminal cytoplasmic tail, cause a
rare condition known as tylosis with esophageal cancer, characterized
by hyperproliferation of epidermal cells, leading to thickening of the
skin on palms and soles, and increased susceptibility to cancer of the
esophagus [98,99]. This is associated with increased ADAM17
maturation and activity on keratinocytes, increased release of EGFR
ligands, and increased EGFR signaling [100]. Interestingly, ADAM17
deficiency has been identified in two siblings and is the likely cause of
autosomal recessive neonatal inflammatory skin and bowel lesions
[101]. Unlike inmice, both survived into childhood, and one is nowan
adult with only repeated skin infections as a symptom [101].
Nevertheless, both studies are consistent with an important role for
iRhom-regulated ADAM17 in epidermal barrier function.
Could iRhom1/ADAM17 and iRhom2/ADAM17 be regarded
as two different molecular scissors?
Both iRhom1 and 2 can interact with ADAM17 and promote its
maturation in a transfected cell line [96]. Both are similarly
activated in a cell line by partial truncations of the N-terminal
cytoplasmic tail, each resulting in increased ADAM17 activity
toward two of its substrates that were tested, TNFR1 and TNFR2
[102]. However, evidence that iRhoms promote the shedding of
distinct ADAM17 substrates has been reported. In a mouse
embryonic fibroblast model for ADAM17-mediated shedding of
a variety of transfected substrates, iRhom2 is critical for the
shedding of heparin-binding EGF-like growth factor, epiregulin,
EphB4, Tie2, and Kit ligand 2, and shedding of the latter is
unaffected by the presence or absence of iRhom1 [103]. TGFα
shedding appears to be promoted by both iRhom1 and iRhom2,
whereas ICAM-1 and L-selectin shedding is independent of
iRhom2, and so may be promoted by iRhom1 [103]. These
differential iRhom effects on ADAM17 shedding may be depen-
dent on cell type, since L-selectin shedding is dependent on
iRhom2 but not iRhom1 in leukocytes [97], which contrasts
with the findings reported in mouse embryonic fibroblasts
[103]. In mouse embryonic fibroblasts, the N-terminal cytoplas-
mic tail of the iRhoms is essential for phorbol ester-induced
ADAM17 shedding [103]. The authors speculate that a key role
for the N-terminal cytoplasmic region, in registering an intracel-
lular signal and somehow inducing activity of its associated
ADAM17, could explain their earlier observation that the cyto-
plasmic tail of ADAM17 is dispensable for induced activation
[23,103]. Taken together, it appears likely that iRhom1 and 2
enable ADAM17 to function as two distinct molecular scissors,
with different substrate specificities and potentially different acti-
vating stimuli. However, given that there are only two iRhoms,
there is substantially less scope for differential regulation of
ADAM17 than for the regulation of ADAM10 by the six
TspanC8s.
The iRhoms are functionally unstudied in platelets.
Quantitative proteomic studies suggest that iRhom2, but not
iRhom1, is expressed by platelets [86,87]. Moreover, the esti-
mated iRhom2 copy number is remarkably similar to that of
ADAM17 in human and mouse platelets (Table 1). As such,
iRhom2 would be predicted to regulate ADAM17 maturation
and trafficking to the cell surface in megakaryocytes, with the
result that ADAM17 expression may be deficient in iRhom2-
knockout platelets.
Conclusions
Within the last 4 years, two distinct types of multi-transmem-
brane proteins have emerged as critical regulators of ADAM10
and ADAM17: the TspanC8 subgroup of tetraspanins and the
iRhom subgroup of inactive rhomboids, respectively.
Accumulating evidence suggests that ADAM10 and ADAM17
can be regarded as different types of molecular scissor, depend-
ing on which TspanC8 or iRhom they are associated with.
Further cell biology research is now required to identify
which substrates are preferentially shed by which ADAM10–
TspanC8 or ADAM17–iRhom complex and to determine the
mechanisms that are responsible for such preferences. For pla-
telet biologists, the platelet-expressed TspanC8s (Tspan14, 15,
and 33) represent potential therapeutic targets for the activation
of ADAM10, with the aim of shedding the pro-thrombotic
collagen receptor GPVI from the platelet surface. Similarly,
6 A. L. Matthews et al. Platelets, Early Online: 1–9
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iRhom2 targeting holds anti-thrombotic potential, by promoting
ADAM17-induced shedding of GPIb.
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